Single-Cell Analysis Market (2026-2036)

The growth of this market is mainly driven by the growing use of single-cell sequencing in cancer, immunology, and neuroscience research, the falling cost per cell of single-cell experiments as instrument-free and highly multiplexed methods scale to millions of cells, the rising use of single-cell data in drug target discovery and cell and gene therapy development, large cell atlas and perturbation projects that generate training data for AI models of biology, and the growing adoption of multiomics workflows that measure RNA, protein, chromatin, and immune receptors in the same cell. However, factors such as the high cost of instruments and sequencing, complex sample preparation, the difficulty of analyzing very large datasets, and constrained academic research budgets in the U.S. and Europe are expected to restrain the growth of this market to some extent.

Single-cell analysis refers to the technologies used to measure the genetic, transcriptional, epigenetic, and protein content of individual cells, rather than the average signal of a bulk tissue sample. By profiling thousands to millions of cells one at a time, researchers can identify rare cell types, map how cells change during development and disease, study how tumors and immune cells respond to treatment, and understand how genetic variation affects individual cells. This report covers single-cell consumables, instruments, and software and services across single-cell transcriptomics, genomics, proteomics, epigenomics, and multiomics. Conventional flow cytometry, which is covered in a separate Meticulous Research report, is excluded, while mass cytometry and other high-parameter single-cell proteomic methods are included.

Single-cell RNA sequencing is the core of the market, and in a typical workflow, a tissue or blood sample is dissociated into single cells or nuclei, each cell is tagged with a unique molecular barcode, and the barcoded RNA is converted into a sequencing library that is read on a next-generation sequencer. Software then assigns each sequencing read to its cell and builds a map of gene expression across all cells. The leading approaches include droplet-based microfluidics, used by 10x Genomics, microwell-based partitioning, used by the BD Rhapsody system and others, and combinatorial or split-pool barcoding, used by Parse Biosciences and others, which does not require a dedicated instrument.

The field has moved quickly from profiling a few hundred cells to profiling millions of cells in one experiment. Combinatorial barcoding kits can now process several million cells and hundreds of samples in a single run, while droplet-based systems have added high-throughput and fixed-sample chemistries. These advances have reduced the cost per cell and made large studies possible, such as cell atlases of entire organs, population-scale immune profiling, and CRISPR perturbation screens that read out the effect of thousands of genetic changes at single-cell resolution.

The market is also expanding beyond RNA. Single-cell multiomics methods measure RNA together with surface proteins, chromatin accessibility, or T-cell and B-cell receptor sequences in the same cell, which gives a more complete view of cell identity and function. Single-cell DNA sequencing is used to study tumor clonal evolution and to detect rare mutations in blood cancers, while mass cytometry and other high-parameter proteomic methods measure dozens of proteins per cell. New methods also allow single-cell analysis of fixed and archived samples, such as FFPE tissue, which opens large clinical sample collections to single-cell research.

Software and data analysis have become a major part of the workflow and a growing source of value. Single-cell experiments generate very large datasets that require specialized computational tools for quality control, clustering, cell type annotation, and integration with other datasets. Vendors are building cloud-based analysis platforms and using AI to automate cell annotation and interpretation, while large public datasets from cell atlas projects are being used to train foundation models of cell biology that can predict how cells respond to genetic changes and drugs.

Academic and research institutes are the largest users of single-cell technologies, supported by funding from the NIH, the European Union, national research agencies, and foundations such as the Chan Zuckerberg Initiative. Pharmaceutical and biotechnology companies are increasingly using single-cell data in target discovery, biomarker development, and cell and gene therapy programs, and clinical research groups are exploring single-cell methods for cancer diagnosis and monitoring.

The market includes single-cell platform providers, sequencing companies, life science tools companies, specialized single-cell startups, and service providers. Leading companies include 10x Genomics, Waters Corporation (BD Biosciences), QIAGEN (Parse Biosciences), Illumina, Thermo Fisher Scientific, Bio-Rad Laboratories, Standard BioTools, Bruker, Takara Bio, Mission Bio, BioSkryb Genomics, Singleron Biotechnologies, MGI Tech, and Miltenyi Biotec.

Over the forecast period, the single-cell analysis market is expected to grow strongly, as the cost per cell continues to fall, as multiomics and fixed-sample methods broaden the range of studies, as pharmaceutical companies use single-cell data and AI models to select drug targets, and as single-cell methods move gradually from research into translational and clinical applications.

Academic and research institutes are expected to account for the largest share of 52.0% of the market in 2026, while pharmaceutical and biotechnology companies are projected to register the highest CAGR.

North America is expected to account for the largest share of 45.0% of the market in 2026, mainly due to high research funding, a large biopharmaceutical industry, and the presence of leading single-cell technology providers.

Asia-Pacific is projected to register the highest CAGR of 14.3% during the forecast period, driven by research investment in China, Japan, South Korea, Singapore, and Australia and the growth of local technology providers.

The report profiles 14 companies, including 10x Genomics, Waters (BD Biosciences), QIAGEN (Parse Biosciences), Illumina, Thermo Fisher Scientific, Bio-Rad, Standard BioTools, Bruker, Takara Bio, Mission Bio, BioSkryb Genomics, Singleron, MGI Tech, and Miltenyi Biotec.